Home
Conditions
Hepadnaviridae Infections

Clinical trial condition

Hepadnaviridae Infections

Explore clinical trials studying Hepadnaviridae Infections. Study availability and eligibility vary by location and protocol.

1,149 public trials 113 recruiting studies

Refine in advanced search Browse all conditions

Hepadnaviridae Infections trial results

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y

NCT00698906

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

NCT00699231

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Brussels, Belgium

View Trial Details

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

NCT00698555

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Ghent, Belgium

View Trial Details

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

NCT00697931

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Leuven, Belgium

View Trial Details

Completed

Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents

NCT00697775

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Mainz, Germany

View Trial Details

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

NCT00697840

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

NCT00697853

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trial Call Center Brussels, Belgium

View Trial Details

Completed

Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B

NCT00698087

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details

Completed

Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine

NCT00697970

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

NCT00696917

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Parkville, Victoria, Australia

GSK Clinical Trials Call Center Hradec Kralové, Czechia

GSK Clinical Trials Call Center München, Germany

GSK Clinical Trials Call Center Bari, Italy

View Trial Details

Hepadnaviridae Infections

Hepadnaviridae Infections trial results

Related conditions